High PLAGL2 mRNA levels were correlated with a worse prognosis in several cancers, including colorectal cancer, HCC, gastric cancer, breast cancer, and urothelial bladder carcinoma (Qu et al., 2018; Li et al., 2019; Fan et al., 2021; Hu et al., 2021; Wu et al., 2021). This evidence concerns the gene PLAGL2 and hepatocellular carcinoma.